[Pharmacokinetics of antineoplastic agents (author's transl)].
The general basis of pharmacokinetics are summarized with the clinical aims of a better utilisation of drugs by the application pharmacokinetic data. The subject is illustrated by some antineoplastic agents especially on high dose methotrexate regimens and clinical use of 5 FU. A pharmacokinetic model may be described with the first agent but for 5 FU no specific model has yet been demonstrated. Some examples of studies on adriamycin and cytosine arabinoside are then given.
D000970:Antineoplastic Agents / Q000378:metabolism*; D003520:Cyclophosphamide / Q000378:metabolism; D003561:Cytarabine / Q000378:metabolism; D004317:Doxorubicin / Q000378:metabolism; D005472:Fluorouracil / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D002955:Leucovorin / Q000494:pharmacology; D008727:Methotrexate / Q000009:adverse effects / Q000378:metabolism
D000970:Antineoplastic Agents; D003561:Cytarabine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate
Intérêt de la pharmacocinétique dans l'utilisation des médicaments anti-cancéreux.